Europe Regenerative Medicine Market 2024–2033

Reports Description

As per the current market research conducted by the CMI Team, the Europe Regenerative Medicine Market is expected to grow with a CAGR of 10.2% from 2023 to 2032. In 2022, the market size is projected to reach a valuation of USD 200.2 million. By 2032, the valuation is anticipated to reach USD 527 million.

The increasing number of people suffering from long-term diseases has emerged as a major driving force for the growth of the market. Focus on the development of stem cell therapies, gene therapies, and tissue engineering has provided the market players with a wide scope for expanding their business.

The advanced therapeutic approaches that have been adopted by the healthcare system after the outbreak of the COVID-19 pandemic have emerged as a major driving force for the growth of the market. Stem cell technologies have provided several solutions for treating various complex diseases. Various clinical trials have been executed by the leading market players to test the efficacy of regenerative medicines worldwide.

Over a couple of years, the demand for regenerative medicines and products based on stem cell therapy is expected to increase by multiple times. The geographical sector of Europe possesses the majority of clinical trials that are being conducted toward regenerative medicine. The existence of various long-term diseases amongst the people residing in this region has emerged as a major opportunity for the growth of the market.

Europe Regenerative Medicine Market - Significant Growth Factors

The Europe Regenerative Medicine Market presents growth opportunities due to multiple factors:

• Increasing prevalence of chronic diseases amongst the European people- a huge number of people residing in the region of Europe suffer from chronic and complex diseases which proves as a major driving force for the growth of the market. Approximately 30% of the people in European countries suffer from chronic diseases. The quality of the health of the people has deteriorated considerably as a result of faulty lifestyle practices. Diseases such as musculoskeletal disorders, neurology disorders, cardiovascular diseases, gastrointestinal disturbances, and cancer have emerged as the most prevalent among people.

• Increasing demand for modern therapeutic techniques- an increase in the spending power of the people has boosted the demand for modern therapeutic techniques and procedures to push the life expectancy of people to new limits. This has in turn boosted the demand for stem cell therapies and gene therapies. The mesenchymal variety of stem cells possesses the capability of penetrating and integrating into various organs which helps it to repair the injuries that are caused. This therapeutic procedure helps to treat injuries to the spinal cord and lungs, cardiovascular system, liver disorders, cartilage diseases, autoimmune disorders, and bone diseases. The inflammation that is produced inside the body of the human being is treated with the help of stem cells.

• Repairing of damaged tissues- Gene and stem cell therapies help to regenerate the failure of the immune system which helps to restore the health of the individual considerably. A huge number of people all over the world are opting for modern therapeutic techniques for treating multiple chronic diseases.

Europe Regenerative Medicine Market - Mergers and Acquisitions

The Europe regenerative medicine market has experienced several mergers and acquisitions in a couple of years, with companies aiming to boost their market presence which helps them to improve their product offerings along with profitability. Some significant examples of mergers and acquisitions in the Europe regenerative medicine market include:

• Amgen which is a US biotech major has agreed to acquire Rodeo which is a private biopharmaceutical company located in the region of Seattle which produces small molecule therapies which are designed to facilitate repair and regeneration of multiple tissues.

• Sumitomo Chemical and Sumitomo Dainippon Pharma have together established S-RACMO Co, which is a joint venture company. This company aims to develop various manufacturing methods for regenerative medicines. The company also indulges in manufacturing the product data required for cell therapy.

• In April 2022- Japan Regenerative Medicine Co. was acquired by Metcela Inc. The former was a completely owned subsidiary by Kidswell Bio Co., Ltd. With the help of this acquisition, Metcela successfully added an autologous cell product, for congenital heart diseases in the pediatric age group. This product was JRM-001.

• In January 2021, ACell Inc., along with its proprietary MatriStem UBM technologies was acquired by LifeSciences. This merger helped to provide multiple solutions for complex wound management.

These mergers and acquisitions assisted the companies to expand their services and product offerings which improved their market value and helped them to capitalize on multiple growth opportunities in the European market. The trend is foreseen to continue which is expected to support the growth of the key market players in the global market.

COMPARATIVE ANALYSIS OF THE RELATED MARKET

Europe Regenerative Medicine Market - Significant Threats

The Europe regenerative medicine market faces numerous significant threats that have an impact on its growth and profitability. Some of these challenges include:

• Lack of skilled professionals: with the evolution of modern therapeutic procedures, the need for skilled professionals has also increased considerably. The lack of skilled professionals proves to be a major setback for the growth of Europe's regenerative medicine market. The functioning of cell therapies and gene therapies is hampered considerably due to a lack of skilled professionals. Despite a strong funding platform, many such challenges hinder the growth of the market.

• High cost of treatment: the cost of treatment is considerably high owing to the modern technology that is being utilized for the treatment procedure. This harms the growth of the market. People with a weaker socioeconomic background are unable to take advantage of modern therapeutic technologies which hamper the growth of the key market players.

• The reimbursement policies: multiple glitches in the reimbursement policies regarding modern therapeutic techniques demoralize the potential consumer which harms the growth of the market. Since gene therapy is in an experimental phase many insurance companies do not provide suitable coverage which leads to a negative impact on the pocket of the common man. Since only FDA-approved treatments receive support from insurance companies, the market of regenerative medicine must face greater challenges.

• Lack of awareness among the people: awareness among the people regarding the available treatment options for chronic and complex diseases has also proved to be a major challenge for the growth of the market. Key market players are making constant efforts to reach out to the common public to expand their client base.

Report Scope

Category-Wise Insights

By Product:

Based on product the segment of tissue engineering has emerged as the leading segment in the European regenerative medicine market. The primary reason for the leading share of this segment is the various advantages that it receives to replace the faulty structure with a living structure that is potent to develop numerous treatment options 4 the people suffering from chronic and complex diseases.

The high investment in the field of research and development that has been made by the government as well as the private sector has proved to be a major blessing for the growth of the market. New products are being launched by the key market players to maintain their position in the global market which again benefits the size of this segment.

By Application:

Musculoskeletal- The segment of musculoskeletal has emerged as the leading segment in the European regenerative medicine market. This segment has emerged as the fastest-growing segment as a result of the various treatment options that it provides the patient with. Numerous chronic and complex diseases benefit from this application which helps to restore the function of the individual. Increasing research and development programs that are carried out by the government as well as private companies have proved to be major driving forces for the growth of this segment.

Oncology- The increasing prevalence of cancer among people as a result of faulty lifestyle practices has boosted the size of this particular segment to a great extent. The introduction of modern therapeutic techniques has also emerged as one of the leading growth factors for the market.

By Material:

Genetically engineered material- The segment of genetically engineered material has emerged as the leading segment in the European regenerative medicine market. The primary reason for the growth of this particular segment is the variety of options that it provides to the healthcare sector for managing various newly introduced complex diseases. The outbreak of the pandemic was one particular example where this segment performed significantly.

To learn more about this report - request a sample report PDF

Europe Regenerative Medicine Market - Regional Analysis

The Europe regenerative medicine market is segmented into multiple regions, including Germany, the United Kingdom, France, Italy, Spain, and the Rest of Europe. Here is a brief overview of each region:

• France- The region of France has emerged as the leading market for the European regenerative medicine market as a result of the increasing acceptance of innovative therapies. Rapidly increasing numbers of chronic and complex diseases among people are dealt with through modern therapeutic techniques. Modern healthcare infrastructure that is provided to the people in this region has also proved to be a major driving force for the growth of the market.

• Germany- The biotechnology sector in the region of Germany is considerably stronger which emerges as a major reason for the growth of the market. The increasing support which is provided by the government and private investors also helps the market to show significant growth in this region.

• United Kingdom- The increasing adoption of robotics and computational tools in the field of medicine has boosted the growth of the market in this particular region.

Competitive Landscape – Europe Regenerative Medicine Market

The Europe regenerative medicine market is decently competitive, with a huge number of market players operating globally. Some of the key players in the market include:

• Integra LifeSciences Corporation
• Aspect Biosystems
• AstraZeneca
• Novartis AG
• Amgen Inc.
• Medtronic plc
• Smith & Nephew plc
• Shenzhen SibionoGeneTech Co. Ltd.
• MiMedx Group
• Baxter
• Others

The various advancements which are made by the key market players in the field of healthcare have helped them to secure their share in the global market. The key market players have majorly concentrated on the commercialization of the instruments which are utilized for surgery. This has helped them to make the surgical procedures simpler and more accessible.

A wide range of equipment and products have been introduced by the key market players in the global market for attracting potential consumers Automation technologies which have been introduced into the market have attracted a huge client base.